Tesaro Inc (TSRO) 25.05 $TSRO
TESARO to Announce First Quarter 2014 Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2014 to discuss the Company's results in greater detail.
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro
GlobeNewswire - Mon Mar 24, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Ben Fidler, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Five Prime Therapeutics didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013 . But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350...
Should You Believe Tesaro's Hype?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
Tesaro's CEO Lonnie Moulder is likely unfazed by the company's eye popping volatility over the past few months. Moulder has a long history of navigating the inherent booms and busts common in emerging biotech. Luckily for Moulder's investors,...
Are We in the Midst of Irrational Exuberance Version 2.0?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 11:10AM CDT
" Clearly, sustained low inflation implies less uncertainty about the future, and lower risk premiums imply higher prices of stocks and other earning assets. We can see that in the inverse relationship exhibited by price/earnings ratios and the rate...
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Tesaro, magicJack VocalTec, and Scientific Games Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 4:15PM CDT
Investors have been waiting for meaningful economic data all week. Following today's fall in the S&P 500 , I believe they'd rather go back to the previous three days when there was little data to speak of. The irony is that today's important...
Why Tesaro, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 12:44PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Tesaro , a clinical-stage...
Partnership With AnaptysBio Gives Tesaro Entree to Immuno-Oncology
Bruce V. Bigelow, The Motley Fool - Motley Fool - Thu Mar 13, 9:30AM CDT
San Diego's AnaptysBio has cut a deal with Tesaro that gives the Waltham, Mass.-based biopharmaceutical a new opening in the hot field of cancer immunotherapy. Under the deal, Anaptys has granted Tesaro exclusive worldwide rights to preclinical...
TESARO and AnaptysBio Announce Collaboration and Exclusive Worldwide License Agreement for Multiple Immuno-Oncology Programs
GlobeNewswire - Thu Mar 13, 6:04AM CDT
-- Immuno-oncology platform provides a portfolio of candidates focused on high value targets, potentially augments the value of other pipeline candidates and enhances prospects for future collaborations to advance TESARO's overall oncology strategy
TESARO to Announce First Quarter 2014 Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2014 to discuss the Company's results in greater detail.
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro
GlobeNewswire - Mon Mar 24, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Ben Fidler, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Five Prime Therapeutics didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013 . But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350...
Should You Believe Tesaro's Hype?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
Tesaro's CEO Lonnie Moulder is likely unfazed by the company's eye popping volatility over the past few months. Moulder has a long history of navigating the inherent booms and busts common in emerging biotech. Luckily for Moulder's investors,...
Are We in the Midst of Irrational Exuberance Version 2.0?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 11:10AM CDT
" Clearly, sustained low inflation implies less uncertainty about the future, and lower risk premiums imply higher prices of stocks and other earning assets. We can see that in the inverse relationship exhibited by price/earnings ratios and the rate...
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Tesaro, magicJack VocalTec, and Scientific Games Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 4:15PM CDT
Investors have been waiting for meaningful economic data all week. Following today's fall in the S&P 500 , I believe they'd rather go back to the previous three days when there was little data to speak of. The irony is that today's important...
Why Tesaro, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 12:44PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Tesaro , a clinical-stage...
Partnership With AnaptysBio Gives Tesaro Entree to Immuno-Oncology
Bruce V. Bigelow, The Motley Fool - Motley Fool - Thu Mar 13, 9:30AM CDT
San Diego's AnaptysBio has cut a deal with Tesaro that gives the Waltham, Mass.-based biopharmaceutical a new opening in the hot field of cancer immunotherapy. Under the deal, Anaptys has granted Tesaro exclusive worldwide rights to preclinical...
TESARO and AnaptysBio Announce Collaboration and Exclusive Worldwide License Agreement for Multiple Immuno-Oncology Programs
GlobeNewswire - Thu Mar 13, 6:04AM CDT
-- Immuno-oncology platform provides a portfolio of candidates focused on high value targets, potentially augments the value of other pipeline candidates and enhances prospects for future collaborations to advance TESARO's overall oncology strategy
